Targeting a key driver of Non-Hodgkin Lymphoma using artificial intelligence
Therapeutic Targeting a Non-Hodgkin Lymphoma Driver Using AI
['FUNDING_R01'] · BAYLOR COLLEGE OF MEDICINE · NIH-10985003
This study is using smart computer technology to find new ways to create medicines that can help people with Non-Hodgkin Lymphoma by targeting specific proteins that are hard to treat, especially those linked to a common gene mutation.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BAYLOR COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10985003 on ClinicalTrials.gov |
What this research studies
This research focuses on using artificial intelligence to discover and optimize inhibitors for specific proteins that drive Non-Hodgkin Lymphoma (NHL). The collaboration between Baylor College of Medicine and Atomwise aims to tackle the challenge of targeting 'undruggable' oncoproteins, particularly those associated with mutations in the MYD88 gene, which is commonly altered in various types of NHL. By leveraging AI technology, the project seeks to enhance the development of new therapeutic options for patients suffering from this cancer. The approach involves analyzing genetic mutations and their effects on immune response to create targeted treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Non-Hodgkin Lymphoma, particularly those with mutations in the MYD88 gene.
Not a fit: Patients with other types of cancers not related to Non-Hodgkin Lymphoma or those without MYD88 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with Non-Hodgkin Lymphoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using AI to identify drug targets in cancer, indicating that this approach could yield significant advancements in treatment.
Where this research is happening
HOUSTON, UNITED STATES
- BAYLOR COLLEGE OF MEDICINE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LI, YONG — BAYLOR COLLEGE OF MEDICINE
- Study coordinator: LI, YONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.